Comparison · NCT00853970-e227d911
Bromfenac Ophthalmic Solution 0.09% vs Placebo: Pain Free
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Bromfenac Ophthalmic Solution 0.09% vs Placebo: Pain Free. Trial comparisons, record NCT00853970-e227d911. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00853970-e227d911
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.888 | 0.828 | 0.929 | wilson | |
| Risk in group 2 | 0.714 | 0.637 | 0.781 | wilson | |
| Risk difference, group 1 minus group 2 | 0.174 | 0.0841 | 0.262 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.24 | 1.11 | 1.4 | log | |
| Odds ratio, group 1 over group 2 | 3.18 | 1.71 | 5.9 | log | |
| Number needed to treat, for one more participant with the outcome on Bromfenac Ophthalmic Solution 0.09% than on Placebo | 5.75 | 3.82 | 11.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Bromfenac Ophthalmic Solution 0.09% | one drop daily in study eye for 2 weeks | 135 | 152 | OG000 |
| Group 2 | Placebo | one drop daily in study eye for 2 weeks | 105 | 147 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Pain Free
- Description
- Participants that are pain free at day 1, taken from patient questionnaire with multiple possible responses measured on a scale of 0-3, where 0=none and 3=severe.
- Time frame
- Day 1
- Population
- Last observation carried forward (LOCF) Analysis, Intent to treat (ITT) Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
- NCT number
- NCT00853970
- Phases
- PHASE3
- Conditions
- Pain, Inflammation
- Interventions
- Bromfenac Ophthalmic Solution, Placebo Comparator
- Lead sponsor
- Bausch & Lomb Incorporated
- Results first posted
- 2011-01-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00853970?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00853970-e227d911